红星资本局12月18日消息，在科创板上市首年，就策划了业绩造假，并且凭借粉饰后的报表，再融资4.34亿元，这样"铤而走险"的事情就发生在医药外包 企业ST诺泰（688076.SH）身上。 12月17日晚，ST诺泰公告称，公司于近日收到中国证监会（简称"证监会"）下发的《行政处罚决定书》，因存在公开发行文件编造重大虚假内容等违法 行为，公司及实际控制人赵德中等6人合计被中国证监会处以7620万元罚款。 造假手法揭秘： "技术转让"与增资形成资金闭环 经过证监会的调查，ST诺泰存在两大违法事实，一是2021年年度报告存在虚假记载；二是公开发行文件编造重大虚假内容。 具体来看，2021年12月，ST诺泰向浙江华贝药业有限责任公司（以下简称浙江华贝）转让药品技术及上市持有许可人权益（以下简称技术转让），并于 12月28日确认业务收入3000万元。 然而，浙江华贝既不具备支付技术转让款的资金实力，也不具备实际应用该技术的生产能力和销售渠道。同期，ST诺泰策划向浙江华贝增资。浙江华贝 向ST诺泰支付的技术转让款最终来自ST诺泰的增资款。 诺泰生物技术转让业务不具有商业实质，不应确认收入。该业务导致诺泰生物2021年年度报 ...

Core Viewpoint - ST Nuotai, a pharmaceutical outsourcing company, engaged in financial fraud during its first year of listing on the STAR Market, resulting in a fine of 76.2 million yuan from the China Securities Regulatory Commission (CSRC) for fabricating significant false content in public offering documents [1][4][18]. Group 1: Fraud Details - ST Nuotai's fraudulent activities included falsely reporting a technology transfer income of 30 million yuan in December 2021, which was not supported by actual business substance [3][17]. - The company confirmed that the technology transfer payment from Zhejiang Huabei Pharmaceutical Co., Ltd. was funded by ST Nuotai's own capital increase, creating a closed-loop funding situation [3][17]. - The inflated revenue of 30 million yuan led to a reported profit increase of 25.95 million yuan, accounting for 20.64% of the total profit disclosed for that period [3][17]. Group 2: Regulatory Actions - The CSRC imposed a total fine of 76.2 million yuan on ST Nuotai and its actual controller Zhao Dezhong, along with five other individuals, for their involvement in the fraudulent activities [1][4][18]. - ST Nuotai's former chairman and vice-chairman were fined a combined 18 million yuan, and the company was ordered to correct its practices and received a warning [4][18]. - The Shanghai Stock Exchange publicly reprimanded ST Nuotai and its responsible individuals, prohibiting the company from applying for refinancing for five years [12][26]. Group 3: Company Background and Financial Performance - ST Nuotai was established in April 2009 and went public on the STAR Market in May 2021, previously gaining market attention due to its involvement in GLP-1 weight loss drugs [21][27]. - For the first three quarters of the current year, ST Nuotai reported a revenue of 1.527 billion yuan, representing a year-on-year increase of 21.95%, and a net profit of 444.54 million yuan, up 26.92% from the previous year [27][28]. - As of December 18, ST Nuotai's stock price was 38.38 yuan per share, with a total market capitalization of 12.1 billion yuan [27][28].

《行政处罚决定书》显示，2021年12月，诺泰生物向浙江华贝药业有限责任公司（以下简称浙江华贝） 转让药品技术及上市持有许可人权益（以下简称技术转让），并于12月28日确认业务收入3,000万元。 浙江华贝既不具备支付技术转让款的资金实力，也不具备实际应用该技术的生产能力和销售渠道。同 期，诺泰生物策划向浙江华贝增资。浙江华贝向诺泰生物支付的技术转让款最终来自诺泰生物的增资 款。诺泰生物技术转让业务不具有商业实质，不应确认收入。该业务导致诺泰生物2021年年度报告虚增 营业收入3,000万元，虚增利润总额2,595.16万元，占当期披露利润总额的20.64%。 来源：环球网 【环球网综合报道】12月17日晚间，江苏诺泰澳赛诺生物制药股份有限公司（以下简称"诺泰生 物"或"ST诺泰（维权）"）公告称，收到中国证监会下发的《行政处罚决定书》。此次处罚涉及上市公 司诺泰生物，以及赵德中、赵德毅、金富强、童梓权、谷海涛、徐东海等6位时任高管被给予警告，并 被罚款，金额总计为7620万元。 《行政处罚决定书》提到两大违法事实，一是2021年年度报告存在虚假记载，二是公开发行文件编造重 大虚假内容。 公开信息显示，诺泰生 ...

Core Viewpoint - The long-standing financial fraud case of Kangde Xin has reached its conclusion, with the Jiangsu Provincial High Court upholding the original verdict, marking the end of the criminal proceedings against the company and its executives [1][3]. Group 1: Legal Outcomes - Kangde Xin was fined a total of 410 million RMB for securities fraud and foreign exchange fraud, with the actual controller and chairman, Zhong Yu, sentenced to 15 years in prison and fined 20.2 million RMB [3]. - Other key personnel received significant prison sentences, including the former general manager Xu Shu, sentenced to 6 years and 6 months, and the former financial director Wang Yu, sentenced to 13 years [3]. - The case involved systematic financial fraud orchestrated by Zhong Yu and other senior management over a period of seven years, severely disrupting the securities market [3]. Group 2: Company Background and Impact - Kangde Xin was once a reputable company in the polymer composite materials sector, known for its high-end materials like optical films, and was considered a "white horse stock" in the market [4]. - The financial fraud led to the company's delisting from the capital market, resulting in significant losses for investors [4]. - The final ruling serves as a strong legal sanction against the perpetrators and emphasizes the regulatory authorities' zero-tolerance stance towards financial fraud in the capital market, reinforcing market integrity and investor rights [4]. Group 3: Financial Implications - Kangde Xin has accounted for the fine in its financial statements, noting that the amount represents 3.29% of its most recent audited net assets, indicating no impact on current or future profits [4]. - The conclusion of the case lays a legal foundation for potential civil compensation and investor rights protection matters in the future [4].

2025年前三季度，ST诺泰营业收入为15.27亿元，同比增长21.95%；归属于上市公司股东的净利润为 4.45亿元，同比增长26.92%。中经记者 晏国文 卢志坤 北京报道 上述处罚金额合计为7620万元。 同期，上交所对ST诺泰及6名高管公开谴责。赵德中被认定为3年不适合担任上市公司董事、监事、高 级管理人员，1年内不接受赵德中控制的其他企业提交的发行上市申请文件，5年内不接受ST诺泰发行 上市申请文件。 ST诺泰方面表示，目前，公司生产经营活动正常有序开展。公司将引以为戒，积极落实整改，进一步 加强内部控制流程建设，提升内控合规。 ST诺泰是一家聚焦多肽药物及小分子化学药，战略布局寡核苷酸业务，进行自主研发与定制研发生产 相结合的生物医药企业，于2021年5月在科创板上市。 【年报和发行文件存虚假记载 ST诺泰及6名高管被处罚7620万元】12月17日晚，科创板上市公司ST诺 泰（688076.SH）披露，收到中国证监会下发的《行政处罚决定书》。因年报和公开发行文件存在虚假 记载，ST诺泰及6名高管被处罚7620万元。 《行政处罚决定书》显示，2021年12月，ST诺泰向浙江华贝药业有限责任公司（以下 ...

《行政处罚决定书》显示，2021年12月，ST诺泰向浙江华贝药业有限责任公司（以下简称"浙江华贝"）转让药品技术及上市许可持有人权益（以下简称"技 术转让"），并于12月28日确认业务收入3000万元。浙江华贝既不具备支付技术转让款的资金实力，也不具备实际应用该技术的生产能力和销售渠道。同 期，ST诺泰策划向浙江华贝增资。浙江华贝向ST诺泰支付的技术转让款最终来自ST诺泰的增资款。ST诺泰技术转让业务不具有商业实质，不应确认收入。 该业务导致ST诺泰2021年年度报告虚增营业收入3000万元，虚增利润总额2595.16万元，占当期披露利润总额的20.64%。另外，该业务还导致ST诺泰2023年 向不特定对象发行可转换公司债券的公开发行文件存在重大虚假内容。 中经记者晏国文卢志坤北京报道 （ST诺泰被上交所纪律处分。 公司公告/图） 12月17日晚，科创板上市公司ST诺泰（688076.SH）披露，收到中国证监会下发的《行政处罚决定书》。因年报和公开发行文件存在虚假记载，ST诺泰及6 名高管被处罚7620万元。 ST诺泰被处罚4740万元，赵德中（实际控制人、时任副董事长）被处罚1300万元，赵德毅（实际控制人 ...

长江商报消息 ●长江商报记者 沈右荣 前高管举报，互联网安全巨头三六零（601360.SH）突然陷入舆论漩涡。 近日，原360高级副总裁、XMAX创始人玉红在社交媒体公开指控，帮助360创始人周鸿祎"做假账几十 亿"。12月16日晚，360集团及周鸿祎双双声明，称玉红言论完全背离事实，影响恶劣，公司不存在财务 造假情形。 受上述风波影响，12月16日、17日，三六零股价连跌，两个交易日市值合计蒸发65.10亿元。 拉长时间来看，自2017年回归A股市场以来，三六零的整体表现低于市场预期。回A股之时，三六零的 股价一度达到66.50元/股，至今累计跌幅超过80%。 三六零盈利承压。2022年以来，公司持续亏损，近4年时间累计亏损超过39亿元。期间，公司保持高强 度研发，年度研发费用均超过30亿元。 备受质疑的是，虽然持续亏损，但自2023年以来，三六零连续派发现金红利，合计派发红利21亿元。 360集团称，针对玉红对360集团、创始人周鸿祎及相关企业家的恶意诽谤，360集团将依法采取法律措 施追究其法律责任，坚决维护企业声誉与合法权益。 360还披露称，经核查，自重组上市以来，2018年至2024年GameWa ...

Core Viewpoint - The case of Yili Clean Energy Co., Ltd. (referred to as "Linen 5") highlights the regulatory stance of "delisting does not exempt from liability" and emphasizes the need for stronger oversight of listed companies and their auditors [1][3]. Group 1: Regulatory Actions and Penalties - Yili Clean Energy was fined 375 million yuan for long-term financial fraud and fraudulent bond issuance, potentially setting a record for penalties against a delisted company in China [1][2]. - The penalties include 210 million yuan for Yili Clean Energy, with the controlling shareholder and 29 responsible individuals facing severe fines and market bans [3]. Group 2: Financial Misconduct Details - From 2016 to 2023, Yili Clean Energy engaged in financial fraud, including inflating profits by over 125 million yuan, assets by over 11 billion yuan, and revenues by over 13 billion yuan [2]. - The company also failed to disclose non-operational fund usage by its controlling shareholder, which amounted to 3.906 billion yuan [2]. Group 3: Governance and Audit Failures - The internal governance of Yili Clean Energy was ineffective, allowing the controlling shareholder to manipulate the company for personal gain, indicating a failure in the board and audit committee's oversight [4]. - The auditing firm, Crowe Horwath, issued unqualified audit reports for seven consecutive years despite the ongoing fraud, raising concerns about their diligence [5]. Group 4: Systemic Issues and Recommendations - The case reveals systemic issues in corporate governance, audit practices, and the existence of a fraudulent industry chain involving third parties [4][5]. - Experts recommend strengthening regulatory frameworks, enhancing investor protection mechanisms, and improving the accountability of auditing firms and third-party collaborators [6][8].

Core Viewpoint - The stock price of 360 (601360) has declined for two consecutive days following allegations of financial fraud, despite the company's attempts to clarify the situation [1][2]. Group 1: Financial Allegations - A former executive, Yu Hong, publicly accused 360 of financial misconduct, claiming that the gaming business fabricated revenue through "self-recharges" and that he could provide evidence [1]. - 360 responded by clarifying that Yu Hong had never held a core management position in the A-share listed company and that his claims were unfounded [2]. Group 2: Business Performance - 360's main business segments include internet services, digital security, and smart hardware, with the gaming business being a core part of internet value-added services [3]. - For the first three quarters of 2025, the company reported revenue of 6.068 billion yuan, a year-on-year increase of 8.18%, ending a six-year decline [3]. - The net profit attributable to shareholders was -122 million yuan, a year-on-year reduction in losses of 78.88%, while the gross profit margin reached a historical high of 67.32%, up 2.57 percentage points year-on-year [3].

北京商报讯（记者 丁宁）12月17日晚间，ST诺泰（688076）发布公告称，公司于近日收到中国证监会 下发的《行政处罚决定书》。 综合上述两项，证监会对ST诺泰责令改正，给予警告，并处以4740万元罚款；对赵德中等相关责任人 给予警告并罚款。 经查明，ST诺泰2021年年度报告存在虚假记载，公司技术转让业务不具有商业实质，不应确认收入。 该业务导致公司2021年年度报告虚增营业收入3000万元，虚增利润总额2595.16万元，占当期披露利润 总额的20.64%。 此外，ST诺泰公开发行文件编造重大虚假内容。如前所述，ST诺泰2021年虚增营业收入3000万元，虚 增利润总额2595.16万元，占当期报告记载利润总额的20.64%，其《募集说明书》中"财务会计信息"相 关内容存在重大虚假内容。 ...